Loading...
XKRX
008930
Market cap1.26bUSD
Apr 09, Last price  
27,050.00KRW
1D
1.12%
1Q
-7.52%
Jan 2017
-55.73%
Name

Hanmi Science Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
15.91
P/S
1.47
EPS
1,700.12
Div Yield, %
0.37%
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
12.00%
Revenues
1.25t
+19.30%
531,396,197,000606,802,686,000689,962,982,000641,470,958,00016,812,302,74019,645,989,150219,862,566,010532,604,690,900776,215,271,160665,284,666,050652,324,367,920707,995,356,120816,618,823,610857,383,419,140950,164,817,3401,046,054,210,8301,247,906,379,060
Net income
115.12b
+66.34%
52,997,718,00071,551,234,00050,526,894,0005,977,013,000-14,690,506,00012,479,133,0009,578,328,00021,312,164,080178,520,883,2207,937,683,00030,068,972,51018,019,525,57030,741,649,30022,601,096,23042,941,995,98069,209,578,700115,121,512,760
CFO
35.16b
+271.98%
-16,175,604,00040,923,068,00060,933,793,00036,493,513,000-7,675,597,550-175,636,290-234,788,3005,245,497,90046,927,261,70076,523,442,300-33,681,816,8402,701,370,43013,024,009,77013,817,514,74013,689,812,1009,451,693,03035,158,260,380
Dividend
Jun 27, 2024100 KRW/sh
Earnings
May 01, 2025

Profile

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi Science Co., Ltd. was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanmiscience.co.kr/
IPO date
Jun 20, 1988
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,247,906,379
19.30%
1,046,054,211
10.09%
Cost of revenue
1,089,168,310
1,899,347,870
Unusual Expense (Income)
NOPBT
158,738,069
(853,293,659)
NOPBT Margin
12.72%
Operating Taxes
15,421,789
4,144,397
Tax Rate
9.72%
NOPAT
143,316,281
(857,438,057)
Net income
115,121,513
66.34%
69,209,579
61.17%
Dividends
(13,332,560)
(13,190,733)
Dividend yield
0.50%
0.59%
Proceeds from repurchase of equity
(7,825,448)
(622,622)
BB yield
0.29%
0.03%
Debt
Debt current
202,967,456
195,520,257
Long-term debt
12,146,099
8,809,483
Deferred revenue
2,932,623
8,303,588
Other long-term liabilities
17,311,773
16,594,044
Net debt
(555,865,547)
(521,522,289)
Cash flow
Cash from operating activities
35,158,260
9,451,693
CAPEX
(8,769,107)
(8,342,387)
Cash from investing activities
(18,675,117)
(2,134,913)
Cash from financing activities
(10,227,974)
(1,076,010)
FCF
157,093,509
(950,714,016)
Balance
Cash
33,578,959
21,513,397
Long term investments
737,400,143
704,338,632
Excess cash
708,583,783
673,549,318
Stockholders' equity
317,533,413
655,112,390
Invested Capital
703,919,526
291,340,276
ROIC
28.80%
ROCE
15.35%
EV
Common stock shares outstanding
67,956
68,494
Price
39,200.00
20.80%
32,450.00
-38.93%
Market cap
2,663,867,713
19.85%
2,222,629,229
-39.04%
EV
2,107,967,684
1,701,108,717
EBITDA
167,470,449
(847,815,212)
EV/EBITDA
12.59
Interest
10,160,601
3,689,325
Interest/NOPBT
6.40%